Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Dose of Remifentanil for Apnoea During Cardiac MRI in Children
NCT02481791Phase 3Unknown
- Sponsor
- Alder Hey Children's NHS Foundation Trust
- Start
- Jul 2015
- Primary completion
- Dec 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 3 trial of remifentanil in congenital heart disease (CHD), sponsored by Alder Hey Children's NHS Foundation Trust. Status: unknown.
02
Drugs
remifentanil
03
Conditions
congenital heart disease (CHD)
Beyond the preview
Go deeper on NCT02481791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02481791.